Articles by Patrick Daly
Data support rituximab over watchful waiting in front-line therapy for low-tumor-burden follicular lymphoma, study concludes.
Ziftomenib, venetoclax, and azacitadine is an close to an all-oral regimen for relapsed/refractory acute leukemias.
The benefit of alternating venetoclax regimens was shown in patients with AML and certain AML subgroups.
Continued treatment and follow-up of patients after the interim analysis demonstrate the durability of response to revumenib.
The confirmed complete response rate of ziftomenib with chemotherapy was high in patients with AML subtypes.
Early signs of clinical activity have been shown in a phase I/II study of tagraxofusp/decitabine in MDS and CMML.
Mature data of three immunotherapy-based hypomethylating agent combinations were presented at ASH.
Interim results suggest acceptable safety and high efficacy of CPX-351 plus ivosidenib.
High complete response rates and low early mortality rates facilitate the majority of patients to allogeneic SCT.
Robust responses with favorable safety has been demonstrated with tisagenlecleucel in relapsed or refractory Fl.
Favorable preclinical outcomes were demonstrated with VX765 treatment.
Tapotoclax was safe and may warrant consideration in combination with other therapies in MDS post-HMA failure.
ESAs had a high rate of failure among patients with lower-risk MDS and often continued treatment despite failure.
Oral azacitidine plus cedazuridine achieved pharmacokinetic equivalence to subcutaneous azacitidine in MDS and MPN.
Retrospective analysis shows that AML treatment strategies are effective for patients with MDS or CMML with NPM1 mutations.
Anti-CD19 CAR T-cell therapy appeared to cure a significant number of patients with relapsed or refractory CLL.
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Pivekimab sunirine showed single-agent activity across multiple doses in the treatment of patients with AML.
Isolating CD34-positive samples from patients with MDS was better able to detect molecular relapse.
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.